Daniel Cobb, MD
Neurology · Gainesville, GANPI 1457568644
Payments from drug & device makers
Across 1,266 payments — averaging $282.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$161K
- Harmony Biosciences LLC$97K
- Philips North America LLC$77K
- H. Lundbeck A S$2K
- AstraZeneca$2K
- UCB, Inc.$2K
- plus $17K from 54 others
Across 2 payments — averaging $873.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
- Eli Lilly$547
What the payments were for
- Consulting fees$6,2008%
- Speaking & faculty fees$47,85859%
- Travel & lodging$4,3465%
- Food & beverage$21,85727%
- Education$3960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Duopa$40,055
- Wakix$8,434
- VYALEV$6,825
- OXTELLAR XR$613
- GOCOVRI$226
- Carto 3$163
- NURTEC ODT$125
How this compares
$357,286 in reported general payments places this provider in the 90th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 225 | $2,546,050 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 11 | $387,061 |
| NuplazidPimavanserin Tartrate | 47 | $263,766 |
| XywavSodium,calcium,mag,pot Oxybate | 13 | $222,713 |
| AustedoDeutetrabenazine | 14 | $169,472 |
| WakixPitolisant Hcl | 20 | $156,655 |
| RytaryCarbidopa/Levodopa | 43 | $88,781 |
| NourianzIstradefylline | 18 | $76,548 |
| Dimethyl Fumarate | 11 | $72,916 |
| CopaxoneGlatiramer Acetate | 11 | $63,122 |
| NeuproRotigotine | 35 | $45,537 |
| UbrelvyUbrogepant | 16 | $43,866 |
| FycompaPerampanel | 24 | $39,002 |
| QuliptaAtogepant | 23 | $37,678 |
| BotoxOnabotulinumtoxina | 27 | $37,233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $518 | $2,546,050225 claims |
| CSL BehringHizentra | $265 | $387,06111 claims |
| Acadia Pharmaceuticals IncNuplazid | $529 | $263,76647 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Copaxone | $721 | $232,59425 claims |
| Harmony Biosciences LLCWakix | $96,705 | $156,65520 claims |
| AbbVieUbrelvy, Qulipta, Botox | $160,955 | $118,77666 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $687 | $93,11374 claims |
| Kyowa Kirin, Inc.Nourianz | $309 | $76,54818 claims |
| UCB, Inc.Neupro | $1,684 | $45,53735 claims |
| Eisai Inc.Fycompa | $424 | $39,00224 claims |
| PfizerEliquis | $759 | $6,50512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 506 neurology providers in Georgia.
Other neurology in Gainesville
- Jonathan LissColumbus$25M
- Marshall NashDecatur$13.6M
- James LahAtlanta$6.8M
- Jonathan GlassAtlanta$5.1M
- Sandeep VaidLawrenceville$4.2M
- Allan LeveyAtlanta$4.2M
- Ben ThrowerAtlanta$3.7M
- Jeffrey EnglishAtlanta$3.1M
- Dennis LaceyAtlanta$2.8M
- David LeschSuwanee$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.